Denali Therapeutics Inc. reported $0 of revenue over the trailing twelve months. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $0 (to Q3 2024). Net income: −$511M, trailing twelve months to Q2 2026. Free cash flow: −$440M, trailing twelve months to Q2 2026. EPS: −$2.84, trailing twelve months to Q2 2026.

DNLIDenali Therapeutics Inc.

Healthcare

$19.46+53% 1Y

$19.46

$13.0552 weeks$26.49

DNLI as reported

Denali Therapeutics Inc. reported $0 of revenue over the trailing twelve months. 9 reported series are charted on this page, each one as filed.

Revenue, trailing twelve months · to Q3 2024 · every figure below is as filed, with no scoring applied

Net income: −$511M
Net income · +6.8% year on year · trailing twelve months to Q2 2026
Free cash flow: −$440M
Free cash flow · +20% year on year · trailing twelve months to Q2 2026
EPS: −$2.84
EPS · +1.1% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for DNLI, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$0	n/a	Q3 2024 · 7 quarters behind
Net income	−$511M	+6.8%	Q2 2026
EPS	−$2.84	+1.1%	Q2 2026
Operating margin	−2573%	n/a	Q3 2023 · 11 quarters behind
Net margin	−2263%	n/a	Q3 2023 · 11 quarters behind
ROE	−55%	n/a	Q2 2026
ROA	−44%	n/a	Q2 2026
Free cash flow	−$440M	+20%	Q2 2026
P/E	111	n/a	Q3 2021 · 19 quarters behind

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.